NOTCH1 and prostate cancer: Indeed, the addition of GSI or monoclonal antibodies against the NRR of Notch1 to docetaxel attenuated the CSC pool and sensitized cells to the chemotherapeutic treatment in experimental models of prostate cancer, breast cancer, NSCLC, and HNSCC [408,449,450,451,452].